Adherence to anti-hypertensive medication Circulatory System Essential (primary) hypertension
Conditions
Interventions
Randomisation will be stratified by pharmacy using the method of random permuted blocks:
Control arm: Medisafe app
Intervention arm 1: Healthera medication reminder ap
Sponsors
University of Cambridge
Cambridgeshire and Peterborough CCG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years of age and over 2. Prescribed any type of blood pressure lowering medication and attending a participating community pharmacy in the East of England or London during the recruitment period 3. Owns a smartphone (Android or iPhone) 4. Has a valid email address 5. Has an adequate understanding of verbal and written English 6. Is able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Is using a pill organiser or similar medication reminder system 2. Is taking part in another research project on medication adherence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at baseline and follow-up meeting (3 months): 1. The proportion of potential participants who cannot participate because of technology issues but who are otherwise eligible 2. Participation rate (the proportion of eligible patients who agree to take part) 3. The number of participants randomised (in total; per pharmacy; and per month) 4. The proportion of participants in each trial arm who download and install the App (uptake rate) 5. The proportion of participants in each trial arm who use the App for 1 week, 1 month and 3 months 6. The proportion of participants who attend the pharmacy for follow-up and provide complete outcome measures 7. The proportion who drop out, reasons for loss to follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline and follow-up meeting (3 months): 1. Medication adherence measured using Medication Adherence Report Scale (MARS) 2. Systolic blood pressure 3. Health status measured using the EQ5D-5L 4. Resource use (additional visits to the pharmacist as a result of using the App) and health service costs (time taken by pharmacist to explain intervention) measured to inform the economic evaluation in the main trial 5. Use of the study interventions and potential mediators of their effects on medication adherence and systolic blood pressure 6. Feasibility/acceptability of the interventions and of conducting a cost-effectiveness trial using qualitative interviews post-trial | — |
Countries
United Kingdom
Contacts
Public ContactJames Jamison
Outcome results
None listed